The Most Efficient Diagnosis of Acute Myeloid Leukemia.
The AMLprofiler simplifies the challenging task to recognize Acute Myeloid Leukemia subtypes and make individualized therapy decisions. It delivers faster results and improved patient classification on an integrated and validated array platform.
In the USA the AMLprofiler is available for research use only.
Download now our new AMLprofiler brochure
The AMLprofiler replaces 7 separate assays based on 3 different technologies: cytogenetics, mutation analysis and expression analysis.Read more
Valk, P.J.M. et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617-1628 (2004). LinkRead more
Skyline Diagnostics and LabPMM GmbH have teamed up to offer comprehensive molecular diagnostic testing for AML:Read more
Age at diagnosis 18 years or older, cytopathologically confirmed diagnosis of AML (including APL and MDS) or RAEB according to the WHO 2008 classification, primary, secondary or relapse, no prior allogeneic or autologous stem cell transplant, no Myeloproliferative Syndrome (MPS)Read more
Rotterdam Science Tower, Marconistraat 16, 3029 AK Rotterdam. The Netherlands, Europe. Phone: +31 (0)10 7038410. Fax: +31 (0)10 7043076. E-mail: firstname.lastname@example.org